Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Quote. Delayed Nyse - 09/22 04:10:00 pm
119.66 USD   +0.98%
09/16INSIDER SELL : Edwards Lifesciences
MT
09/13INSIDER SELL : Edwards Lifesciences
MT
09/09INSIDER SELL : Edwards Lifesciences
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
120.69(c) 119.42(c) 117.99(c) 118.5(c) 119.66(c) Last
1 906 637 3 695 327 2 448 393 1 360 245 1 495 519 Volume
-0.27% -1.05% -1.20% +0.43% +0.98% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5 341 M - -
Net income 2021 1 422 M - -
Net cash position 2021 1 542 M - -
P/E ratio 2021 52,1x
Yield 2021 -
Sales 2022 5 902 M - -
Net income 2022 1 511 M - -
Net cash position 2022 2 564 M - -
P/E ratio 2022 48,8x
Yield 2022 -
Capitalization 74 587 M 74 587 M -
EV / Sales 2021 13,7x
EV / Sales 2022 12,2x
Nbr of Employees 14 900
Free-Float 96,6%
More Financials
Company
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas:... 
More about the company
Ratings of Edwards Lifesciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about EDWARDS LIFESCIENCES CORPORATION
09/16INSIDER SELL : Edwards Lifesciences
MT
09/13INSIDER SELL : Edwards Lifesciences
MT
09/09INSIDER SELL : Edwards Lifesciences
MT
09/05HOUSTON WE HAVE : Edwards Lifesciences to Fund Houston We Have's Clinical Trial of ECHOiQ'..
MT
08/03EDWARDS LIFESCIENCES : Goldman Sachs Adjusts Edwards Lifesciences' Price Target to $105 fr..
MT
08/02EDWARDS LIFESCIENCES : Raymond James Adjusts Edwards Lifesciences' Price Target to $122 fr..
MT
08/02EDWARDS LIFESCIENCES : initiates $100 million social impact investment fund to advance rac..
PU
07/30EDWARDS LIFESCIENCES : Management's Discussion and Analysis of Financial Condition and Res..
AQ
07/30TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 5, 2021.
CI
07/30TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 8, 2019.
CI
07/30EDWARDS LIFESCIENCES : Oppenheimer Adjusts Edwards Lifesciences PT to $120 From $97 on Str..
MT
07/30EDWARDS LIFESCIENCES : Wells Fargo Adjusts Price Target on Edwards Lifesciences to $115 Fr..
MT
07/30EDWARDS LIFESCIENCES : Credit Suisse Raises Edwards Lifesciences' PT to $126 from $112 Aft..
MT
07/30EDWARDS LIFESCIENCES : Jefferies Adjusts Price Target on Edwards Lifesciences to $130 From..
MT
07/30EDWARDS LIFESCIENCES : Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $..
MT
More news
News in other languages on EDWARDS LIFESCIENCES CORPORATION
09/16VENTE PAR DES INITIÉS : Edwards Lifesciences
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2017Les valeurs à suivre à Wall Street
2017Les valeurs à suivre à Wall Street
2017Wall Street se replie légèrement, Trump ne surprend pas sur la fiscalité
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Stock Trading Strategies
EDWARDS LIFESCIENCES CORPORATION - 09/08
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 119,66 $
Average target price 117,83 $
Spread / Average Target -1,53%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors